What is the best treatment for patients with human papillomavirus–positive and –negative oropharyngeal cancer?

E-ISSN： 1097-0142|120|10|1462-1470

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.10, 2014-05, pp. : 1462-1470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The discovery that the human papilloma virus (HPV) is associated with a high and increasing percentage of oropharyngeal squamous cell carcinomas (SCCs) is among the most significant advances in the field of head and neck oncology. HPV‐positive oropharyngeal cancer (HPVOPC) has clinical, etiologic, pathologic, and molecular features that distinguish it from HPV‐negative disease. Increasingly, HPVOPC is being diagnosed in clinical practice because of the easy availability of p16 immunohistochemistry, a surrogate marker of HPV. The superior prognosis of HPVOPC has led to a reexamination of treatment approaches, and clinical trials are currently investigating strategies to deintensify treatment to reduce acute and late toxicity while preserving efficacy. This is of particular interest in low‐risk patients. Unfortunately, patients with HPV‐negative tumors still have high rates of locoregional failure and more efficacious treatments are required. This review of oropharyngeal SCC focuses on current and investigational treatment strategies in patients with both HPV‐positive and HPV‐negative oropharyngeal SCC. Cancer 2014;120:1462–1470. © 2014 American Cancer Society.